Clinical trial / 2015
Short-term fasting reduced hematological toxicity from chemotherapy in breast cancer patients.
Thirteen women with HER2-negative stage II or III breast cancer receiving chemotherapy were randomized to fast for 24 hours before and after infusion or follow standard dietary guidelines. Seven days post-chemotherapy, mean erythrocyte counts (P = 0.007, 95% CI 0.106 to 0.638) and thrombocyte counts (P = 0.00007, 95% CI 38.7 to 104) were significantly higher in the fasting group. Fasting also prevented an acute post-chemotherapy rise in peripheral blood mononuclear cell DNA damage.
- Study type
- Randomized controlled trial
- Who was studied
- 13 women with HER2-negative stage II/III breast cancer
- What was measured
- hematological toxicity and chemotherapy-induced DNA damage
THE PAPER
The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study.
de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, Houtsma D, Putter H, van der Hoeven JJ, Nortier JW, Pijl H, Kroep JR. BMC Cancer, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.